Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Jose Ovalles Jaquez

Internal Medicine San Juan, PR Medical Doctor

NPI 1083834139 CMS profile 593365

Calle Padre Las Casas #107 Urbanizacion El Vedado, San Juan, PR 00918

Open in the dashboard

General payments

$61

2 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Jose Ovalles Jaquez of San Juan, PR is reported in the CMS Open Payments database as having received $61 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 21st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $61 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Ovalles Jaquez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Ovalles Jaquez were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Ovalles Jaquez Internal Medicine median Middle half National median
2019 $61 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2019
  1. Janssen Pharmaceuticals, Inc $34 1 payment
  2. Amgen Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $61 2 payments
Products named General payments · program year 2019
  1. XARELTO $34 1 payment
  2. Repatha $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

4,061

Median for Internal Medicine: 777

Drug cost

$181,789

Median for Internal Medicine: $73,373

Branded share of claims

22.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 41 $25,375
Synjardy Xr Empagliflozin/Metformin Hcl Brand 28 $17,543
Eliquis Apixaban Brand 25 $17,119
Jentadueto Linagliptin/Metformin Hcl Brand 33 $16,533
Xarelto Rivaroxaban Brand 27 $15,624
Ozempic Semaglutide Brand 14 $13,956
Synthroid Levothyroxine Sodium Brand 297 $13,460
Janumet Sitagliptin Phos/Metformin Hcl Brand 15 $8,602
Jentadueto Xr Linagliptin/Metformin Hcl Brand 16 $8,508
Farxiga Dapagliflozin Propanediol Brand 12 $7,061

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record